Guest guest Posted October 13, 2011 Report Share Posted October 13, 2011 IN THIS ISSUE Free Webinar: Fri., Oct. 14. Related Resources New at Research1st Quick Links ABOUT USLINK ARCHIVEDONATE NOW Free Webinar: Fri., Oct. 14. Join us tomorrow, Oct. 14, 2011, to hear from leaders of the Blood XMRV Scientific Research Working Group (SRWG) about the results of their study reported last month in Science. Free registration: https://www1.gotomeeting.com/register/606452768 Background:A report in Oct. 2009 linked CFS to the retrovirus xenotropic murine leukemia virus-related virus (XMRV). In late 2009 the Blood XMRV Scientific Research Working Group was formed by the U.S. Department of Health and Human Services to design and carry out a study to determine whether XMRV posed a threat to blood safety. The two year effort involved nine labs, three federal agencies and dozens of scientists across the country. Results from Phase I of the study were reported in July 2010 at a meeting of the Food and Drug Administration's Blood Products Advisory Committee (BPAC). Phase II results were presented at a BPAC meeting in December 2010 and in a webinar. Phase III results were published on Sept. 22, 2011 in Science and presented at the IACFS/ME conference in Ottawa on Sept. 23, 2011. Study leaders will repeat the Ottawa presentation via a webinar with open registration, thus enabling a larger number of stakeholders to hear directly about the study design, results and conclusions. Drs. Busch, Graham and Kleinman will discuss consequences for blood safety and the understanding of these agents' role in CFS. Written questions can be submitted at the time of registration or by participants during the webinar.Webinar Details:Date: October 14, 2011Time: 4:00 PM - 5:00 PM (Eastern time)Speakers: Graham , PhD of Blood Systems Research Institute Busch, MD, PhD of Blood Systems Research Institute Kleinman, BSc, MD of University of British Columbia Free registration: https://www1.gotomeeting.com/register/606452768 Related Resources For more information about the Sept. 22, 2011 report in Science of the Phase III results, please visit http://www.research1st.com/2011/09/22/study-summaries/For more information about XMRV, please visit http://www.research1st.com/2011/09/13/the-x-factor/For a list of XMRV-related articles and publications, please visit http://www.cfids.org/xmrv/resource-listing.aspFor information about blood donation by individuals with CFS, please visit http://www.cfids.org/blood.aspFor the recording of the Phase ll results webinar, please visit New at Research1st.com Dr. Lapp shares his summary of the recent IACFS/ME conference held in Ottowa. Kewley provides an analysis of how to calculate the burden of ME/CFS, and why it's important to do so. Our Mission: For CFS to be widely understood, diagnosable, curable and preventable. Our Strategy: To stimulate research aimed at the early detection, objective diagnosis and effective treatment of CFS through expanded public, private and commercial investment. Our Core Values: To lead with integrity, innovation and purpose. Forward to a friend This email was sent to carlene.grimshaw@... by cfidslink@... | The CFIDS Association of America | PO Box 220398 | Charlotte | NC | 28222-0398 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.